Avidity Partners Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Avidity Partners Management’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-12,967	Closed	-$289K	–	48
2026 Q1	$289K	Sell	12,967 -93,933	-88%	-$2.24M	0.06%	44
2025 Q4	$2.86M	Sell	106,900 -37,100	-26%	-$887K	0.82%	27
2025 Q3	$3.07M	Buy	+144,000	New	+$3.41M	0.7%	32
2025 Q2	–	Sell	-169,000	Closed	-$2.81M	–	57
2025 Q1	$2.81M	Buy	+169,000	New	+$3.07M	0.54%	48
2024 Q2	–	Sell	-588,500	Closed	-$10.9M	–	86
2024 Q1	$10.9M	Buy	+588,500	New	+$14.6M	0.35%	71
2022 Q1	–	Sell	-300,000	Closed	-$7M	–	93
2021 Q4	$7M	Sell	300,000 -250,000	-45%	-$5.03M	0.15%	67
2021 Q3	$9.14M	Sell	550,000 -390,000	-41%	-$7.52M	0.2%	72
2021 Q2	$22.9M	Buy	+940,000	New	+$21.2M	0.62%	49
2021 Q1	–	Sell	-527,600	Closed	-$28.2M	–	95
2020 Q4	$28.2M	Buy	+527,600	New	+$26.2M	0.92%	40
2020 Q2	–	Sell	-357,000	Closed	-$15.1M	–	58
2020 Q1	$15.1M	Buy	357,000 +303,000	+561%	+$12.5M	2.08%	17
2019 Q4	$2.31M	Buy	+54,000	New	+$2.35M	1.46%	28

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Avidity Partners Management's ACAD Position: Q2 2026 in Review

Avidity Partners Management sold out of Acadia Pharmaceuticals (ACAD) in Q2 2026, closing a stake of 12,967 shares — an estimated $289K sold.

Avidity Partners Management first reported a position in ACAD in Q4 2019 and held it in 11 quarters. The position peaked at $28.2M in Q4 2020. 352 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

Avidity Partners Management reported no remaining Acadia Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Avidity Partners Management sold 12,967 Acadia Pharmaceuticals shares in Q2 2026, an estimated $289K.
Avidity Partners Management first reported a position in Acadia Pharmaceuticals in Q4 2019 and held it in 11 quarters.
Avidity Partners Management's Acadia Pharmaceuticals position peaked at $28.2M in Q4 2020.
352 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Avidity Partners Management's 13F filing for Q2 2026, filed 14 Aug 2026.